Latest news with #Tune
Business Wire
13-05-2025
- Business
- Business Wire
Novotech Wins Citeline CRO Partnership of the Year Award for Strategic Collaboration with Tune Therapeutics
SYDNEY--(BUSINESS WIRE)--Novotech a globally recognized full-service clinical research organization (CRO) and scientific advisory company, is proud to announce it has been awarded the Citeline CRO Partnership of the Year Award in recognition of its collaboration with Tune Therapeutics, a pioneering epigenetic editing company. This honor celebrates the teams' partnership and sets a benchmark for CRO–biotech partnerships. Novotech and Tune Therapeutics' partnership focuses on a groundbreaking clinical trial program advancing an epigenetic therapy with the potential to revolutionize the treatment landscape for Chronic Hepatitis B. Share The CRO Partnership of the Year award honors outstanding collaboration between a CRO and a pharmaceutical or biotech company that has advanced clinical programs through strong alignment and shared goals. Sarah Anderson, Director of Therapeutic Strategy, and Steve Roan, Associate Director of Business Development, accepted the award on behalf of Novotech at the Citeline Awards ceremony held on May 8, 2025, in Boston. Katie Tarashuck, Vice President of Finance at Tune Therapeutics, attended as a partner representative. Novotech and Tune Therapeutics' partnership focuses on a groundbreaking clinical trial program advancing an epigenetic therapy with the potential to revolutionize the treatment landscape for Chronic Hepatitis B (CHB). The partnership combines Novotech's regulatory, operational, and therapeutic expertise with Tune's innovative scientific platform and agile development strategy. 'This recognition from Citeline reflects not only the strength of our partnership with Tune Therapeutics but also the dedication of our global teams to help bring novel therapies to patients faster,' said Dr. John Moller, CEO of Novotech. 'We are honored to collaborate with visionary biotech companies like Tune and look forward to continuing to deliver clinical excellence across the development spectrum.' 'Tune is delighted to receive this partnership award with Novotech," said Dr. Heidi Zhang, Chief Development Officer at Tune Therapeutics. "Together, we have achieved a global first in bringing this epigenome editing therapy to the clinic, and new hope to over 250 million people living with CHB worldwide.' The award acknowledges Novotech's ability to align closely with biotech partners, applying its regulatory and therapeutic expertise to support the effective delivery of clinical trials across varied global settings. 'The strength of this collaboration,' added Dr. Zhang, 'lies in our shared commitment to transparency, willingness to confront challenges directly, and ability to act quickly and effectively as one team.' About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results. For more information or to speak to an expert team member visit epigenome editing or genetic tuning) that enables the targeted control of gene expression without cutting or resequencing DNA. Armed with its powerful and innovative genetic tuning platform (TEMPO), Tune Therapeutics aims to bring gene, cell, and regenerative therapies into a new era of human medicine – expanding their range of application to common and chronic diseases.
Business Wire
13-05-2025
- Business
- Business Wire
Novotech憑藉與Tune Therapeutics的策略合作榮膺Citeline CRO年度合作夥伴關係獎
澳洲雪梨--(BUSINESS WIRE)--(美國商業資訊)-- 作為一家可提供全方位服務的國際性受託研究機構 (CRO) 和科學諮詢公司，Novotech有幸榮膺Citeline CRO年度合作夥伴關係獎。這項殊榮表彰了Novotech與表觀基因編輯龍頭企業Tune Therapeutics之間的策略合作，嘉許了雙方團隊之間的卓越合作夥伴關係，並為CRO與生物技術公司之間的合作夥伴關係樹立了業界新標杆。 Novotech 與 Tune Therapeutics 的合作重點是一項有潛力徹底改變慢性乙型肝炎治療格局的表觀遺傳療法的突破性臨床試驗計劃。 Share CRO年度合作夥伴關係獎旨在表彰CRO與製藥或生物技術公司之間的出色合作。為實現共同目標，雙方勠力同心，致力於推動臨床研究計畫的發展。 治療策略總監Sarah Anderson和業務開發副總監Steve Roan在2025年5月8日於波士頓舉行的Citeline頒獎典禮上代表Novotech受獎。Tune Therapeutics財務副總裁Katie Tarashuck作為合作夥伴代表出席了頒獎典禮。 Novotech和Tune Therapeutics之間的策略合作聚焦於一項開創性臨床試驗計畫，該計畫旨在推動表觀基因療法取得突破性進展，有望徹底改變慢性B型肝炎 (CHB) 的治療格局。雙方的合作夥伴關係將使Novotech的監管、營運和臨床方面的專業知識與Tune的創新科學研發平台和靈活開發策略深度融合。 Novotech執行長John Moller博士表示：「Citeline對我們的認可不僅體現了我們與Tune Therapeutics之間堅實的合作夥伴關係，同時也彰顯了我們的國際團隊致力於幫助患者更快地獲得新型療法的承諾。能與Tune等具有遠見卓識的生物技術公司合作，我們倍感榮幸。同時，我們也期待繼續在療法開發領域提供卓越的臨床服務。」 Tune Therapeutics開發長Heidi Zhang博士表示：「Tune很高興能與Novotech共同受獎。我們攜手進行了創新，將表觀基因組編輯療法融入臨床研究，為全球逾2.5億CHB患者帶來了新曙光。」 這項殊榮認可了Novotech與生物技術合作夥伴之間的通力合作能力，對於該公司運用其監管和臨床專業知識，在多樣化全球環境下有效展開臨床試驗給予肯定。 Zhang博士還表示：「合作的優勢在於我們共同承諾提高透明度、願意直迎挑戰，並能夠組建團隊以迅速有效地採取對策的能力。」 关于 Novotech Novotech是一家可提供全方位服務的國際性受託研究機構 (CRO) 和科學諮詢公司，在藥物研發的各個階段提供指導，深受生物技術及中小型製藥公司的信賴。 Novotech業務涉及全球多個國家和地區，在亞太地區、北美和歐洲設有30多個辦事處，並與5000多個試驗中心建立了合作關係，透過提供關鍵臨床試驗資源網絡、廣泛接觸不同的受試者群體，幫助客戶加速將前沿的治療方法推向市場。 Novotech透過以客戶為中心的服務模式，將人員、流程和技術無縫整合，提供定制化解決方案，推動變革性的治療方法進入市場。Novotech採用真正的合作夥伴關係模式，堅定地致力於幫助客戶取得成功、推動創新並促進全球醫療保健的發展。Novotech憑藉卓越的臨床試驗執行和創新能力獲得了眾多業界榮譽，包括連續19年蟬聯Frost & Sullivan CRO年度公司獎 (Frost & Sullivan CRO Company of the Year)。Novotech在臨床以及法規方面深厚的專業知識，以及對本地市場的深刻洞察，使其能夠為臨床試驗的順利進行、資料分析的強化以及加速受試者招募策略方面提供支援。 Novotech與客戶攜手，將科學進步轉化為能夠改善全球健康狀況的治療方法，實踐推動創新、創造卓越成果的使命。
Yahoo
18-03-2025
- Sport
- Yahoo
Talkin' controversy over UNC's NCAA entry, Duke's chances, High Point University
HIGH POINT, N.C. (WGHP) — Pull up a chair, because we are '' on Tuesday, March 18! FOX8's and are ditching the script and telling you their real thoughts on topics all across the athletic world. They've got plenty of hot takes, and you can catch it all on K.C. & Danny Talkin' Sports Tune in using the video player above or stream it live on , and . You can also watch it on the on Roku, AppleTV and Fire TV. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
USA Today
05-03-2025
- Sport
- USA Today
Cardinals free agent preview: Quarterback
Cardinals free agent preview: Quarterback With free agency approaching, a look at the Cardinals' offseason needs at the quarterback position. NFL free agency begins next week on Monday with the opening of the contact and negotiation window with players whose contracts expire on March 12 and become free agents. The Arizona Cardinals will be active, although it is uncertain how aggressive they will be or how much money they will spend. But before that happens, we will take a look at each position group, see who is on the roster, who will be free agents and what their need at the position is for the offseason. Let's look at the quarterback position. Quarterbacks under contract Kyler Murray: Signed through 2028, $43.3 million cap hit in 2025 Clayton Tune: Signed through 2026, $1.12 million cap hit in 2025 Pending free agents None Offseason need They will add a third quarterback and perhaps a fourth to the roster for the offseason, but how they go about it will say a lot about what they think of Tune. They traded for Desmond Ridder last offseason and he was expected to be the backup, but Tune beat him out. If they like him to continue as the backup moving forward, they can bring in a young, developing guy or someone of similar experience to compete for the job. If they go out an add a more experienced and more expensive backup, then it shows that they want something more than they think Tune can be. Notable free agent quarterbacks This list doesn't include players like Daniel Jones or Sam Darnold, who both feel they are starting quarterbacks and will look for starting opportunities or at least jobs that could become starting opportunities. Coming to Arizona means knowing he is the backup. Zach Wilson Trey Lance Jacoby Brissett Taylor Heinicke Drew Lock Marcus Mariota Tyler Huntley Get more Cardinals and NFL coverage from Cards Wire's Jess Root and others by listening to the latest on the Rise Up, See Red podcast. Subscribe on Spotify, YouTube or Apple podcasts.
Yahoo
01-03-2025
- Climate
- Yahoo
Storm chasers say National Weather Service data critical to chasers, meteorologists' jobs
OKLAHOMA CITY (KFOR) — Following reports that employees at the National Weather Service (NWS) in Norman would be fired as part of massive on going federal cuts, storm chasers say they want the public to know how vital NWS data is for them, and any meteorologists you may follow, to keeping bringing life-saving forecasts and information. 'I was really afraid of storms as a kid,' said storm tracker Conner Tune, with News 4's 4Warn Storm was until Tune had a close brush with the power of Mother Nature himself.'I grew up in the town of Bridge Creek, and was there in '99 when we got hit,' Tune said. NOAA layoffs impacting National Weather Services workers in Oklahoma He became, maybe even a little obsessed.'My fear turned into a real deep fascination,' Tune harnessed that fascination and became a storm the past several years, he's been a storm tracker for News 4's 4Warn Storm showed News 4 his chasing vehicle, the 4Warn 'Weather Wrangler.' His Weather Wrangler has all the bells and whistles. The most important of them might be his iPad, full of apps bringing him the latest data from the National Weather Service. 'The computer models that we look at to plan where we should stage for days of severe weather,' Tune said. 'It's hard to know where tornadoes are gonna be on days where there's tornadoes. We rely on that data, that observed data from the Weather Service to make an educated guess. It takes many, many teams all working together.' That's why, when he heard the news that the National Weather Service will not be immune to the ongoing federal cuts, he grew concerned.'Without those people, none of that data is going to be collected,' Tune said. It brought back that old childhood feeling. 'It's scary,' Tune said. 'Without the data, we're blind.' He says it wouldn't just put storm chasers in the dark, but also every TV and social media meteorologist too. 'No matter what you choose to gather your weather information, the fact is all of these organizations are reliant upon this information, this data gathered by the National Weather Service,' Tune said. 'They're not gathering this data themselves.' Now, with storm season fast approaching, he'll still be hitting the road.'I'm playing an important role in public safety,' said Tune. He just hopes he won't encounter too many bumps along the way.'I do think we need to be very vocal,' Tune said. 'We all, as Oklahomans, we should know the importance of our weather service.' Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
